Iparomlimab and Tuvonralimab for intermediate trophoblastic tumors
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) for a rare type of pregnancy-related tumor called intermediate trophoblastic tumor. It may help women whose disease has spread, come back, or is resistant to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and between 18 and 70 years old.
- You have a confirmed diagnosis of placental site trophoblastic tumor (PSTT) or epithelioid trophoblastic tumor (ETT).
- For Cohort A: Your cancer is stage IV, has come back after treatment, or no longer responds to chemotherapy.
- For Cohort B: Your cancer is stage I to III and you need chemotherapy after surgery, with risk factors like high beta-hCG levels, incomplete removal, or certain features seen under a microscope.
- You have a good performance status (ECOG 0 or 1), meaning you can do most daily activities without help.
- Your blood counts, liver and kidney function, and blood clotting tests are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is tracking how well a combination of two immunotherapy medicines (iparomlimab and tuvonralimab) works in people with advanced cancers. It's a real-world study, meaning you get the treatment as part of your regular care, and the researchers observe the results.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) before and after surgery for people with a certain type of lung cancer that can be removed. It aims to see if this treatment helps improve outcomes.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemoradiation for locally advanced cervical cancer caused by HPV. It may be an option for women with stage 3-4A disease or positive lymph nodes who have not had immunotherapy before.
This trial tests a new drug called QL706 combined with chemotherapy, with or without another drug called bevacizumab, for people with cervical cancer that has returned or spread and no longer responds to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemoradiation can help people with cervical cancer that has returned or spread to a few new places. The goal is to see if this combination improves outcomes for those whose cancer is no longer responding to initial treatment.
This trial tests a new immunotherapy drug (QL1706) combined with hormone therapy for breast cancer that is hormone receptor positive and HER2 negative, but did not respond well to initial chemotherapy. The goal is to see if this combination can shrink tumors before surgery and potentially improve outcomes.
Hear when a new Intermediate Trophoblastic Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.